PGM2L1

Across TCGA pan-cancer cohorts, PGM2L1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PGM2L1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PGM2L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGM2L1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LGG, and HNSC are the cancer types where PGM2L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.098	0.768	<.001	18	view →
LGG	OS	Median	All	0.294	0.811	.004	6	view →
HNSC	DFS	Median	All	0.209	0.710	.032	6	view →
UCEC	DFS	Median	III,IV	0.906	0.534	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PGM2L1–LUAD (DFS)

Open the LUAD breakdown →